Research Topics
| T J SchnitzerSummaryAffiliation: Northwestern University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Calcaneal quantitative ultrasound compared with hip and femoral neck dual-energy x-ray absorptiometry in people with a spinal cord injuryThomas J Schnitzer
Department of Physical Medicine and Rehabilitation, Northwestern University Feinberg School of Medicine, 710 N Lake Shore Drive, Room 1020, Chicago, Il 60611 Electronic address
PM R 4:748-55. 2012..To evaluate the sensitivity and specificity of calcaneal quantitative ultrasound (QUS) measurements for identifying osteoporosis determined by dual-energy x-ray absorptiometry (DXA) at the hip in a spinal cord injury (SCI) population...
A preliminary fMRI study of analgesic treatment in chronic back pain and knee osteoarthritisMarwan N Baliki
Department of Physiology, Northwestern University, Feinberg School of Medicine, 303 East Chicago Ave, Chicago IL 60611, USA
Mol Pain 4:47. 2008..Moreover, lidocaine patch treatment modulates distinct brain circuitry in each condition, yet in OA we observe divergent results with fMRI and with questionnaire based instruments...
Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trialThomas J Schnitzer
Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
Arthritis Rheum 51:549-57. 2004..To compare the efficacy and tolerability of the novel cyclooxygenase 2-selective inhibitor lumiracoxib with placebo and diclofenac in osteoarthritis (OA)...- Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studiesThomas J Schnitzer
Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
J Rheumatol 32:1093-105. 2005..5 mg (n=259), or rofecoxib 25 mg (n=527) in a double blind trial [Vioxx, Acetaminophen, Celecoxib Trial (VACT2)]. Results were also pooled with the similarly designed VACT1 trial... - Update on guidelines for the treatment of chronic musculoskeletal painThomas J Schnitzer
Department of Medicine, Northwestern University Feinberg School of Medicine, 710 North Lake Shore, 10th Floor, Chicago, IL 60611, USA
Clin Rheumatol 25:S22-9. 2006.... - A 4-week randomized study of acetaminophen extended-release vs rofecoxib in knee osteoarthritisT J Schnitzer
Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Osteoarthritis Cartilage 17:1-7. 2009..To compare the safety and efficacy of acetaminophen extended-release (APAP ER) with rofecoxib for the management of pain associated with knee osteoarthritis (OA)... - Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter studyT J Schnitzer
Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Osteoarthritis Cartilage 18:629-39. 2010..To evaluate the efficacy and safety of the cyclooxygenase-inhibiting nitric-oxide donator, naproxcinod, compared with naproxen and placebo in patients with osteoarthritis (OA) of the knee... - Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee painT J Schnitzer
Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Osteoarthritis Cartilage 19:639-46. 2011..This study was designed to evaluate the long-term safety and effectiveness of repeated doses of the humanized anti-nerve growth factor antibody, tanezumab, during open-label treatment of patients with OA knee pain... - A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritisThomas J Schnitzer
Northwestern University Feinberg School of Medicine, 710 N Lake Shore Drive, Chicago, IL 60611, USA
Clin Rheumatol 30:1433-46. 2011..Lumiracoxib was similar to celecoxib for all three co-primary endpoints. All treatments were well tolerated. In conclusion, lumiracoxib is effective in reducing pain and improving function in hip OA patients... - Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the kneeThomas J Schnitzer
Northwestern Center for Clinical Research, Chicago, Illinois 60611, USA
Arthritis Rheum 53:827-37. 2005.... - An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritisThomas J Schnitzer
Northwestern Center for Clinical Research, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
Clin Ther 25:3162-72. 2003..However, these conclusions are limited by lack of clinical information (other than an OA or RA diagnosis), inability to ascertain actual use, and potential for selection bias... - Efficacy of tramadol in treatment of chronic low back painT J Schnitzer
Office of Clinical Research and Training, Northwestern University, Chicago, IL 60611, USA
J Rheumatol 27:772-8. 2000..To evaluate the efficacy and safety of tramadol in the treatment of chronic low back pain... - Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trialThomas J Schnitzer
Office of Clinical Research and Training, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Lancet 364:665-74. 2004.... - A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysisChin Lee
Northwestern University, The Feinberg School of Medicine, Chicago, Illinois, USA
Arthritis Rheum 51:746-54. 2004.... - Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritisChin Lee
Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, USA
Arthritis Rheum 53:510-8. 2005..To evaluate the role of common internal controls in a meta-analysis of the relative efficacy of cyclooxygenase 2-selective inhibitors (coxibs) in the treatment of osteoarthritis (OA)... - Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studiesThomas J Schnitzer
Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Curr Med Res Opin 21:151-61. 2005..001). Lumiracoxib was well tolerated in all studies. CONCLUSIONS: These studies provide initial evidence that lumiracoxib is an effective, well-tolerated agent for the treatment of chronic and acute pain... - Knee pain and joint loading in subjects with osteoarthritis of the kneeD E Hurwitz
Department of Orthopedic Surgery, Section of Rheumatology, Rush Presbyterian St Luke s Medical Cente, Chicago, Illinois 60612, USA
J Orthop Res 18:572-9. 2000..Additional long-term prospective studies are needed to determine whether increased loading during walking actually results in accelerated progression of the disease... - Osteoarthritis management: the role of cyclooxygenase-2-selective inhibitorsT J Schnitzer
Office of Clinical Research and Training, Northwestern University Medical School, Chicago, Illinois 60611, USA
Clin Ther 23:313-326; discussion 311-2. 2001..The most recent OA guidelines from the American College of Rheumatology were published in 2000 because new therapies such as the COX-2-selective inhibitors had been introduced for the management of OA... - Severity of joint pain and Kellgren-Lawrence grade at baseline are better predictors of joint space narrowing than bone scintigraphy in obese women with knee osteoarthritisSteven A Mazzuca
Department of Medicine, Indiana University School of Medicine IUSM, Indianapolis, 46202, USA
J Rheumatol 32:1540-6. 2005.... - Update of ACR guidelines for osteoarthritis: role of the coxibsThomas J Schnitzer
Office of Clinical Research and Training, Northwestern University Medical School, Evanston, IL 60611, USA
J Pain Symptom Manage 23:S24-30; discussion S31-4. 2002..It is anticipated that the guidelines for the management of OA will continue to evolve as new therapies become available... - Tanezumab for the treatment of pain from osteoarthritis of the kneeNancy E Lane
Department of Medicine, University of California at Davis Medical School, Sacramento, CA 95817, USA
N Engl J Med 363:1521-31. 2010..This proof-of-concept study was designed to investigate the safety and analgesic efficacy of tanezumab, a humanized monoclonal antibody that binds and inhibits nerve growth factor... - COX-2-selective inhibitors in the treatment of arthritisThomas J Schnitzer
Office of Clinical Research and Training, Northwestern University School of Medicine, Chicago, IL 60611, USA
Cleve Clin J Med 69:SI20-30. 2002..The use of coxibs to treat OA and RA is recommended as first-line therapy when symptoms of pain and inflammation are present in patients vulnerable to potential NSAID-associated GI toxicity... - Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: analysis of a large United States claims databaseT J Schnitzer
Office of Clinical Research and Training, Northwestern University, Chicago, Illinois, USA
Clin Ther 23:1984-98. 2001..Prior GPA use was the strongest predictor of subsequent concomitant GPA/ NSAID use. Differences in GPA use were observed among patients using different NSAIDs... - Update on alendronate for osteoporosis: once-weekly dosingT J Schnitzer
Northwestern University, Clinical Research and Training, Chicago, Illinois 60611, USA
Expert Opin Pharmacother 2:1461-72. 2001..Sales data several months after introduction of once-weekly alendronate into the marketplace demonstrate rapid and extensive acceptance of this new regimen... - A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back painThomas J Schnitzer
Office of Clinical Research and Training, Northwestern University, Chicago, Illinois, USA
J Pain Symptom Manage 28:72-95. 2004..More rigorously designed trials should be implemented to establish comparative efficacy and safety of drugs used to treat chronic and acute LBP... - Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritisDaniel O Clegg
Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
N Engl J Med 354:795-808. 2006..The multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) evaluated their efficacy and safety as a treatment for knee pain from osteoarthritis... - Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trialMichael E Farkouh
Cardiovascular Clinical Research Center, New York University School of Medicine, 530 First Avenue, New York, NY 10016, USA
Lancet 364:675-84. 2004.... - Serious lower gastrointestinal clinical events with nonselective NSAID or coxib useLoren Laine
University of Southern California School of Medicine, Los Angeles 90033, USA
Gastroenterology 124:288-92. 2003..We performed a post hoc analysis of serious lower GI clinical events with a nonselective NSAID and a COX-2-selective agent in a prospective, double-blind, randomized GI outcomes trial... - Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trialGregory P Geba
Merck and Co Inc, US Human Health, PO Box 4, West Point, PA 19486 0004, USA
JAMA 287:64-71. 2002..Osteoarthritis (OA) is often treated with nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or specific inhibitors of cyclooxygenase 2 (COX-2)... - Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trialKenneth D Brandt
Indiana University School of Medicine, Rheumatology Division, Indianapolis, IN 46202 5100, USA
Arthritis Rheum 52:2015-25. 2005..To confirm preclinical data suggesting that doxycycline can slow the progression of osteoarthritis (OA). The primary outcome measure was joint space narrowing (JSN) in the medial tibiofemoral compartment... - Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studiesSteven S Smugar
Merck and Co, Inc, West Point, PA 19486 0004, USA
Curr Med Res Opin 22:1353-67. 2006..To compare the efficacy of rofecoxib and celecoxib for the treatment of knee or hip OA over 6 weeks... - Pain management today - optimising the benefit/risk ratio: defining the role of weak opioids and combination analgesicsThomas J Schnitzer
Clin Rheumatol 25:S1. 2006 - Response to expression of concern regarding VIGOR studyClaire Bombardier
N Engl J Med 354:1196-9. 2006 - Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trialSusan L Greenspan
University of Pittsburgh Osteoporosis Prevention and Treatment Center, 1110 Kaufmann Building, 3471 Fifth Avenue, Pittsburgh, PA 15213, USA
Ann Intern Med 136:742-6. 2002..001). CONCLUSION: Alendronate increased BMD at both the spine and hip in elderly female residents of long-term care facilities... - Subject retention and adherence in a randomized placebo-controlled trial of a disease-modifying osteoarthritis drugSteven A Mazzuca
Indiana University School of Medicine, Indianapolis, 46202 5100, USA
Arthritis Rheum 51:933-40. 2004..To describe the methods by which remarkable levels of subject retention and adherence were achieved in a 30-month multicenter randomized placebo-controlled trial (RCT) of a disease-modifying osteoarthritis drug (DMOAD)... - Means, responders, and meaning: evaluation of clinical trials in osteoarthritisThomas J Schnitzer
Arthritis Rheum 48:3001-3. 2003